Aryx Therapeutics I Performance
| ARYXDelisted Stock | USD 0.0005 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Aryx Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Aryx Therapeutics I has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong basic indicators, Aryx Therapeutics is not utilizing all of its potentials. The current stock price disturbance, may contribute to short-term losses for the investors. ...more
| Total Cashflows From Investing Activities | 8.4 M |
Aryx |
Aryx Therapeutics Relative Risk vs. Return Landscape
If you would invest 0.05 in Aryx Therapeutics I on September 15, 2024 and sell it today you would earn a total of 0.00 from holding Aryx Therapeutics I or generate 0.0% return on investment over 90 days. Aryx Therapeutics I is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Aryx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aryx Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aryx Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Aryx Therapeutics I, and traders can use it to determine the average amount a Aryx Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ARYX |
Based on monthly moving average Aryx Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aryx Therapeutics by adding Aryx Therapeutics to a well-diversified portfolio.
Aryx Therapeutics Fundamentals Growth
Aryx Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Aryx Therapeutics, and Aryx Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aryx Pink Sheet performance.
| Return On Asset | -0.75 | ||||
| Current Valuation | 237.58 K | ||||
| Shares Outstanding | 33.46 M | ||||
| Price To Book | 37.83 X | ||||
| EBITDA | (14.18 M) | ||||
| Cash And Equivalents | 2.95 M | ||||
| Cash Per Share | 0.09 X | ||||
| Debt To Equity | (5.11) % | ||||
| Book Value Per Share | (0.23) X | ||||
| Cash Flow From Operations | (34.97 M) | ||||
| Earnings Per Share | (0.59) X | ||||
| Total Asset | 12.41 M | ||||
| Retained Earnings | (187.11 M) | ||||
| Current Asset | 8.62 M | ||||
| Current Liabilities | 8.49 M | ||||
About Aryx Therapeutics Performance
Evaluating Aryx Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Aryx Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aryx Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California. ARYX THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on PNK Exchange. It employs 56 people.Things to note about Aryx Therapeutics performance evaluation
Checking the ongoing alerts about Aryx Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Aryx Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aryx Therapeutics is not yet fully synchronised with the market data | |
| Aryx Therapeutics has some characteristics of a very speculative penny stock | |
| Aryx Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.46, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Aryx Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Aryx Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Aryx Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Aryx to invest in growth at high rates of return. When we think about Aryx Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (33.17 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aryx Therapeutics I currently holds about 2.95 M in cash with (34.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from investing.com: Earnings call transcript Oil-Dri Q1 2025 sees record sales, stock rises |
- Analyzing Aryx Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aryx Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Aryx Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aryx Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aryx Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aryx Therapeutics' pink sheet. These opinions can provide insight into Aryx Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Aryx Pink Sheet
If you are still planning to invest in Aryx Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aryx Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |